BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 26921086)

  • 1. Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
    Campbell P; Thomas CM
    J Oncol Pharm Pract; 2017 Mar; 23(2):143-147. PubMed ID: 26921086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.
    O'Connor OA; Horwitz S; Masszi T; Van Hoof A; Brown P; Doorduijn J; Hess G; Jurczak W; Knoblauch P; Chawla S; Bhat G; Choi MR; Walewski J; Savage K; Foss F; Allen LF; Shustov A
    J Clin Oncol; 2015 Aug; 33(23):2492-9. PubMed ID: 26101246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.
    Foss F; Advani R; Duvic M; Hymes KB; Intragumtornchai T; Lekhakula A; Shpilberg O; Lerner A; Belt RJ; Jacobsen ED; Laurent G; Ben-Yehuda D; Beylot-Barry M; Hillen U; Knoblauch P; Bhat G; Chawla S; Allen LF; Pohlman B
    Br J Haematol; 2015 Mar; 168(6):811-9. PubMed ID: 25404094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma.
    Lee HZ; Kwitkowski VE; Del Valle PL; Ricci MS; Saber H; Habtemariam BA; Bullock J; Bloomquist E; Li Shen Y; Chen XH; Brown J; Mehrotra N; Dorff S; Charlab R; Kane RC; Kaminskas E; Justice R; Farrell AT; Pazdur R
    Clin Cancer Res; 2015 Jun; 21(12):2666-70. PubMed ID: 25802282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
    Rashidi A; Cashen AF
    Future Oncol; 2015; 11(11):1659-64. PubMed ID: 26043217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Belinostat for the treatment of peripheral T-cell lymphomas.
    McDermott J; Jimeno A
    Drugs Today (Barc); 2014 May; 50(5):337-45. PubMed ID: 24918834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Belinostat: first global approval.
    Poole RM
    Drugs; 2014 Sep; 74(13):1543-54. PubMed ID: 25134672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of new agents for peripheral T-cell lymphoma.
    Ito Y; Makita S; Tobinai K
    Expert Opin Biol Ther; 2019 Mar; 19(3):197-209. PubMed ID: 30658046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520.
    Puvvada SD; Li H; Rimsza LM; Bernstein SH; Fisher RI; LeBlanc M; Schmelz M; Glinsmann-Gibson B; Miller TP; Maddox AM; Friedberg JW; Smith SM; Persky DO
    Leuk Lymphoma; 2016 Oct; 57(10):2359-69. PubMed ID: 26758422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UGT genotyping in belinostat dosing.
    Goey AK; Figg WD
    Pharmacol Res; 2016 Mar; 105():22-7. PubMed ID: 26773202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study.
    Walewski J; Paszkiewicz-Kozik E; Borsaru G; Hellmann A; Janikova A; Warszewska A; Mais A; Ammendola A; Herz T; Krauss B; Henning SW
    Leuk Lymphoma; 2019 Mar; 60(3):675-684. PubMed ID: 30160566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Belinostat: clinical applications in solid tumors and lymphoma.
    Molife LR; de Bono JS
    Expert Opin Investig Drugs; 2011 Dec; 20(12):1723-32. PubMed ID: 22046971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
    Coiffier B; Federico M; Caballero D; Dearden C; Morschhauser F; Jäger U; Trümper L; Zucca E; Gomes da Silva M; Pettengell R; Weidmann E; d'Amore F; Tilly H; Zinzani PL
    Cancer Treat Rev; 2014 Oct; 40(9):1080-8. PubMed ID: 25199959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study.
    Kirschbaum MH; Foon KA; Frankel P; Ruel C; Pulone B; Tuscano JM; Newman EM
    Leuk Lymphoma; 2014 Oct; 55(10):2301-4. PubMed ID: 24369094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.
    Hopfinger G; Nösslinger T; Lang A; Linkesch W; Melchardt T; Weiss L; Egle A; Greil R
    Ann Hematol; 2014 Mar; 93(3):459-62. PubMed ID: 24441915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral T-cell lymphoma.
    Reimer P; Chawla S
    J Hematol Oncol; 2013 Sep; 6():69. PubMed ID: 24020452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial.
    Tan D; Phipps C; Hwang WY; Tan SY; Yeap CH; Chan YH; Tay K; Lim ST; Lee YS; Kumar SG; Ng SC; Fadilah S; Kim WS; Goh YT;
    Lancet Haematol; 2015 Aug; 2(8):e326-33. PubMed ID: 26688485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
    Shi Y; Dong M; Hong X; Zhang W; Feng J; Zhu J; Yu L; Ke X; Huang H; Shen Z; Fan Y; Li W; Zhao X; Qi J; Huang H; Zhou D; Ning Z; Lu X
    Ann Oncol; 2015 Aug; 26(8):1766-71. PubMed ID: 26105599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma.
    Marchi E; Raufi AG; O'Connor OA
    Hematol Oncol Clin North Am; 2017 Apr; 31(2):359-375. PubMed ID: 28340883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Belinostat (Beleodaq) for peripheral T-Cell lymphoma.
    Med Lett Drugs Ther; 2015 Apr; 57(1467):e66-7. PubMed ID: 25988963
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.